Jazz Pharmaceuticals to Acquire Rare Epilepsy Drugmaker in $1.3 Billion Deal

Jazz Pharmaceuticals is reportedly in the process of acquiring a company specializing in rare epilepsy drugs, in a deal potentially valued at $1.3 billion.